Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Metastatic Disease Clinical Trial Setting

Known as: METASTATIC 
A clinical trial or treatment setting in which the therapy of interest is used to treat metastatic disease.
National Institutes of Health

Related topics

Related topics

2 relations
CDISC SDTM Treatment Setting TerminologyClinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
CONTEXT Invasive bladder cancer is a frequently occurring disease with a high mortality rate despite optimal treatment. The… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Highly Cited
2017
Highly Cited
2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
Abstract Background Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall… Expand
  • figure 1
  • figure 1
  • figure 2
  • figure 2
  • table 1
Highly Cited
2015
Highly Cited
2015
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
BACKGROUND Prostate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2015
Highly Cited
2015
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
BACKGROUND Cabazitaxel, abiraterone acetate (AA), and enzalutamide have been approved for the treatment of patients with… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2015
Highly Cited
2015
MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCND1
Metastasis is a leading cause of mortality for osteosarcoma patients. The molecular pathological mechanism remains to be… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Highly Cited
2014
Highly Cited
2014
Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
BACKGROUND Vismodegib, a first-in-class Hedgehog pathway inhibitor, was US Food and Drug Administration (FDA) approved for… Expand
  • figure 1
  • table I
  • table II
  • figure 2
  • figure 3
Highly Cited
2013
Highly Cited
2013
Segmentation, Feature Extraction, and Multiclass Brain Tumor Classification
Multiclass brain tumor classification is performed by using a diversified dataset of 428 post-contrast T1-weighted MR images from… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Highly Cited
2012
Highly Cited
2012
Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study.
PURPOSE We evaluated the feasibility of administering carboplatin as a radiosensitizer during craniospinal radiation therapy… Expand
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 4
Highly Cited
2004
Highly Cited
2004
CCI‐779 in metastatic melanoma
CCI‐779 is an analog of the immunosuppressive agent, rapamycin, that has demonstrated activity against melanoma in preclinical… Expand
Highly Cited
2001
Highly Cited
2001
Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease
Little is known about the genetic regulation of medulloblastoma dissemination, but metastatic medulloblastoma is highly… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE